Highlights
About
Macrophage Reprogramming Cell Therapies for Life-threatening Diseases
Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming. The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications. The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials. In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Identity
| Name | Enlivex Therapeutics |
|---|---|
| Slug | enlivex-therapeutics |
| Former names | Tolarex |
| Type / kind | startup |
| Crunchbase ID | enlivex-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6Tj-8JDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Mar 2019;Public on TASE on Jul 2019; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Einstein St 14, Nes Ziona, Israel |
Web & social
| Website | https://enlivex.com |
|---|---|
| Careers page | http://enlivex.com/careers |
| https://www.linkedin.com/company/19117645 | |
| Twitter / X | https://twitter.com/EnlivexT |
| YouTube | https://www.youtube.com/channel/UCGJI8b2YMny7Gxu3mMrQlPg |
Classifications
Funding
| Total raised | $286.9M |
|---|---|
| Current stage | Public |
| Market cap | $174.2M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}